checkAd

     422  0 Kommentare Algeta schedules first quarter 2013 results presentation, webcast and conference call

    Oslo, Norway, 7 May 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its first quarter 2013 results on Wednesday, 15 May 2013. A presentation by Algeta's senior management team to investors, analysts and the press will take place in Oslo at 10:00 CET.

    The presentation will also be webcast live and can be accessed through www.algeta.com where questions can also be submitted during the presentation.

    The presentation will take place at 10:00 CET at:

    Shippingklubben
    Haakon VIIs gate 1
    0161 Oslo
    Norway.

    Algeta's senior management will also host an international conference call at 14:30 CET/08:30 Eastern Time (US) (details below).  

    To participate in the conference call, please dial the appropriate number below five minutes prior to the call:

    US: +1 877 423 0830
    UK: +44 20 7153 9154
    Norway: +47 21 06 61 13
    Sweden: +46 8-506 443 86
    Denmark: +45 32 71 42 62
    Switzerland: +41 44 580 65 22

    Participant pin code: 281404#

     

    To access the replay, please dial:

    US: +1 877 679 2989
    UK: +44 20 3364 5196
    Norway: +47 23 50 02 03
    Sweden: +46 8-505 564 73

    Conference reference: 346423#

    A replay version of the conference call will also be available at www.algeta.com.

    The results report and the presentation will be available at www.algeta.com in the Investors section from 07:00 CET.

    ###

    For further information, please contact:

    Mike Booth / Renate Birkeli +47 23 00 67 32
    Communications & Corporate Affairs ir@algeta.com
    Media enquiries:
    Mark Swallow +44 207 638 9571
    Citigate Dewe Rogerson mark.swallow@citigatedr.co.uk
    Knut Ekern +47 22 04 82 00
    Gambit Hill & Knowlton knut.ekern@hkstrategies.com
    Kari Watson +1 781 235 3060
    MacDougall Biomedical Communications kwatson@macbiocom.com  
    US investor enquiries:
    Tricia Swanson +1 646 378 2953
    The Trout Group tswanson@troutgroup.com

    About Algeta
      
    Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

    This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



    This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

    The owner of this announcement warrants that:
    (i) the releases contained herein are protected by copyright and other applicable laws; and
    (ii) they are solely responsible for the content, accuracy and originality of the
    information contained therein.

    Source: Algeta ASA via Thomson Reuters ONE

    HUG#1699177



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Algeta schedules first quarter 2013 results presentation, webcast and conference call Oslo, Norway, 7 May 2013 - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, will announce its first quarter 2013 results on Wednesday, 15 May 2013. A presentation by Algeta's senior management …